Cohance Lifesciences Ltd vs Divis Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 454.6 as of 05 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 69.8 on March 2025 . This represents a CAGR of 7.51% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 153257 crore on March 2025 . This represents a CAGR of 9.72% over 5 years The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The revenue of Divis Laboratories Ltd for the Dec '25 is ₹ 2692 crore as compare to the Sep '25 revenue of ₹ 2860 crore. This represent the decline of -5.87% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The ebitda of Divis Laboratories Ltd for the Dec '25 is ₹ 904 crore as compare to the Sep '25 ebitda of ₹ 1033 crore. This represent the decline of -12.49% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 583 crore over 7 quarters. This represents a CAGR of 19.00% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 35.99 % on March 2025 . This represents a CAGR of 5.79% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
It is among the largest pharmaceutical companies in India with a portfolio of approx.

FAQs for the comparison of Cohance Lifesciences Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Divis Laboratories Ltd?

Market cap of Cohance Lifesciences Ltd is 17,391 Cr while Market cap of Divis Laboratories Ltd is 176,617 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Divis Laboratories Ltd?

The stock performance of Cohance Lifesciences Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Divis Laboratories Ltd?

As of May 5, 2026, the Cohance Lifesciences Ltd stock price is INR ₹454.6. On the other hand, Divis Laboratories Ltd stock price is INR ₹6653.05.

How do dividend payouts of Cohance Lifesciences Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.